Based on the key indicators related to Aligos Therapeutics' liquidity, profitability, solvency, and operating efficiency, Aligos Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Aligos Therapeutics' Common Stock Shares Outstanding is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 193.1 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 11.7 M in 2024. Key indicators impacting Aligos Therapeutics' financial strength include:
Investors should never underestimate Aligos Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Aligos Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Aligos Therapeutics.
Net Income
(92.06 Million)
Aligos
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Sale Purchase Of Stock
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Net Working Capital
Short Term Debt
Property Plant Equipment
Retained Earnings Total Equity
Capital Surpluse
Non Current Liabilities Other
Tax Provision
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past Aligos Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aligos Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Aligos Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Aligos Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aligos Therapeutics. Check Aligos Therapeutics' Beneish M Score to see the likelihood of Aligos Therapeutics' management manipulating its earnings.
Aligos Therapeutics Stock Summary
Aligos Therapeutics competes with Tff Pharmaceuticals, Eliem Therapeutics, Inhibrx, and Enliven Therapeutics. Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Aligos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Aligos Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Aligos Therapeutics's current stock value. Our valuation model uses many indicators to compare Aligos Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aligos Therapeutics competition to find correlations between indicators driving Aligos Therapeutics's intrinsic value. More Info.
Aligos Therapeutics is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At this time, Aligos Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Aligos Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Aligos Therapeutics Systematic Risk
Aligos Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Aligos Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Aligos Therapeutics correlated with the market. If Beta is less than 0 Aligos Therapeutics generally moves in the opposite direction as compared to the market. If Aligos Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Aligos Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Aligos Therapeutics is generally in the same direction as the market. If Beta > 1 Aligos Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Aligos Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aligos Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Aligos Therapeutics growth as a starting point in their analysis.
Aligos Therapeutics December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Aligos Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aligos Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aligos Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Aligos Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aligos Therapeutics's daily price indicators and compare them against related drivers.
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.